Search results
AstraZeneca aims for $80 bln in total revenue by 2030
Reuters· 4 days ago, opens new tab aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday,...
AstraZeneca Targets $80B Revenue by 2030 Through Pipeline Expansion
Market Watch· 4 days agoBy Helena Smolak AstraZeneca has set out a target to grow revenue to $80 billion by 2030 as it aims to bolster its investment in technologies and platforms....
AstraZeneca to build $1.5-billion cancer drug plant in Singapore
Reuters via Yahoo News· 5 days agoThe facility, which will be the drugmaker's first end-to-end ADC production site, will be supported...
AstraZeneca Aims for $80 Billion in Sales by 2030
Bloomberg· 4 days agoHave a confidential tip for our reporters? AstraZeneca Plc aims to almost double sales to $80 billion by 2030 as Chief Executive Officer Pascal Soriot...
AstraZeneca to harness China's 'explosion' of innovation to boost cell therapy R&D
FierceBiotech· 3 days agoAstraZeneca’s growing presence in China will play a key role in the Big Pharma’s cell therapy...
Pfizer wins cancer drug patent case against AstraZeneca
Pharmaceutical Technology via Yahoo Finance· 5 days agoThe US District Court for the District of Delaware has ordered AstraZeneca to pay $107.5m to Pfizer...
AstraZeneca shares rise as pharma group unveils 2030 revenue target By Investing.com
Investing.com· 3 days agoU.K.-listed shares in AstraZeneca (LON:AZN) rose in morning trading on Tuesday after the...
...Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal...
FOX 59 Indianapolis· 2 days agoUnder the terms of the agreement, Nona Biosciences shall receive US$19 million upon completion...
Boston Properties Prevails in Kendall Square Fight
The Real Deal· 1 day agoSuffolk County Superior Court Judge Kenneth Salinger determined the construction of AstraZeneca’s future lab space in Cambridge’s Kendall Square didn’t...
AstraZeneca aims increase its annual revenue by 75% in its post-COVID era
Quartz· 3 days agoCambridge, U.K.-based pharmacuetical giant AstraZeneca announced an ambitious sales goal for the end of this decade, just as it pulls it COVID-19 vaccines off the shelves.